Title Image


Launched or under launch (2012-2016): Australia, Colombia, Djibouti, Dubai, Egypt, Finland, France, Israel, Malaysia, Middle east, New Zealand,, South Africa, South Korea, Tunisia…


1st Topical MMP Inhibitor
for the Treatment of Chronic Wounds

CHRONIC WOUNDS: Bedsores, Diabetic Ulcers, Venous Leg Ulcers, Surgical Wounds
Physiopathology: Situated on the surface of the body, all chronic wounds are highly prone to contamination, particularly with bacteria & cell debris. To clean the wounds, our body produces >20 proteolytic enzymes (MMPs) to break “proteins” into smaller molecules, but these MMPs equally destroy Extra-Cellular matrix (ECM) essential for daughter cell attachment & growth. In the absence of ECM, new cells cannot attach nor grow, and the wound cannot heal.

Ideal Treatment Approach: In theory, wound healing should be very simple as it merely requires filling the wound cavity with new cells. An ideal treatment should neutralize ECM-destroying MMPs, remove contaminants & keep the wound surface hydrated.

Currently Available Treatments:
• Specific ECM-destroying MMP inhibitors: None; Cell growth stimulators: None (Growth factors are proteins & are destroyed by MMPs). No treatment for 30 million patients in Europe alone!!
• Symptomatic: Hydrogels, hydrating bandages, antiseptics, in vitro bioengineered skin…
VITROBIO‘s Completely NEW Therapeutic Approach: Specific MMP antagonists in a natural hydrating & antiseptic solution.
Employing in vitro epidermis models, Vitrobio identified ECM-destroying MMPs (Matrix Metallo-Proteinases). MMPs are proteins and certain plant procyanidins (PCDs), which are very big & inert natural plant molecules, have a strong affinity for specific proteins. Therefore, we identified specific MMP-antagonist PCDs.
These PCDs were incorporated into a glycerol-based viscous liquid (VB-Gly), 18 times more osmotically active than sea water yet NON-IRRITANT (International patent 1997: PCT/FR99/01340). A new patent on a filmogen VB-Gly solution was recently filed (N° PCT/EP2013/061835). When applied as a thin layer on the wound surface, ANTISCAR immediately forms a film & creates a strong outward flow of hypotonic liquid, instantly detaching all the contaminants & PCD-MMP conjugates from the wound surface. The wound-cleaning function of MMPs is replaced by the long-lasting, outward flow of hypotonic liquid induced by VB-Gly, which equally protects the wound surface & keeps it hydrated.
Product Presentation: Viscous Solution in 50mL Tube.
Directions: Topical application to form a film over the wound surface, 2-3 times per day until complete recovery.
Regulatory Status: Due to the purely mechanical topical filmogen activity without any pharmacological, biological, metabolic or immunological interaction with the cellular structure: Class IIa Medical Device in Europe.
Contraindications: Not to be used in conjunction with any cell-unfriendly treatment (antiseptics, chemicals)
Side Effects: None
Clinical Efficacy: Full trial published in Diabetes Research and Clinical Practice. 92: 92-99, 2011; ISSN: 0168-8227.